Viracta Therapeutics Provides Clinical Update and Outlook for 2024

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803921/0/en/Viracta-Therapeutics-Provides-Clinical-Update-and-Outlook-for-2024.html

Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mid-2024

Read more at globenewswire.com

Related news for (VIRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.